NFKB1 and neoplasm: Many doxorubicin-resistant tumor cells have upregulated NF-κB activity that promotes survival (Enzler et al., 2011; Esparza-López et al., 2013), suggesting that combination treatment with a proteasome inhibitor may be effective at overcoming doxorubicin resistance.